EpiCept has priced its public offering of 3.33 million shares of its common stock at $1.50 per share and five-year warrants to purchase up to approximately 1.66 million shares of common stock at an exercise price of $1.50 per share.
Subscribe to our email newsletter
EpiCept will receive approximately $4.7 million in net proceeds from the offering. Rodman & Renshaw, a subsidiary of Rodman & Renshaw Capital Group acted as placement agent.
EpiCept intends to use the net proceeds for general corporate purposes.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.